NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
Russia starts phase 3 trials of its first domestic HPV vaccine
01 July 2022
Free medicines provision was suggested for patients with ischemia
01 July 2022
30 June 2022
A project on remote sale of prescription drugs has been presented
30 June 2022